EXEL:NASDAQExelixis, Inc. Analysis
Data as of 2026-04-01 - not real-time
$44.04
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Exelixis is trading comfortably above its short‑term moving averages, with momentum indicators such as the MACD histogram turning positive and the RSI indicating moderate strength. The stock sits near a short‑term resistance level but benefits from stable volume and a supportive technical backdrop.
Fundamentally, the company delivers exceptional profitability, boasting a near‑perfect gross margin and strong operating returns, while its price‑to‑earnings multiple sits well below the biotechnology industry average, suggesting a valuation discount. A solid cash position, modest debt, and a forward‑looking earnings outlook further reinforce the upside case, even as a recent insider sale adds a modest near‑term caution.
Fundamentally, the company delivers exceptional profitability, boasting a near‑perfect gross margin and strong operating returns, while its price‑to‑earnings multiple sits well below the biotechnology industry average, suggesting a valuation discount. A solid cash position, modest debt, and a forward‑looking earnings outlook further reinforce the upside case, even as a recent insider sale adds a modest near‑term caution.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price hovering near short‑term resistance
- Bullish MACD and stable volume
- Recent insider share sale adds slight caution
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Valuation discount relative to biotech peers
- Strong profit margins and cash generation
- Forward earnings growth expected to accelerate
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Robust pipeline of oncology and specialty drugs
- Low beta and solid balance sheet reduce market volatility
- Sustained demand for high‑margin cancer therapies
Key Metrics & Analysis
Financial Health
Revenue Growth5.60%
Profit Margin33.73%
P/E Ratio15.8
ROE35.53%
ROA19.26%
Debt/Equity9.30
P/B Ratio5.3
Op. Cash Flow$884.3M
Free Cash Flow$631.2M
Industry P/E25.8
Technical Analysis
TrendNeutral
RSI61.1
Support$40.24
Resistance$44.19
MA 20$41.79
MA 50$42.72
MA 200$41.57
MACDBullish
VolumeStable
Fear & Greed Index77.61
Valuation
Fair Value$43.70
Target Price$46.83
Upside/Downside6.34%
GradeFair
TypeBlend
Risk Assessment
Beta0.64
Volatility31.58%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.